泼尼松联合吗替麦考酚酯治疗重症肌无力疗效分析

目的：探讨泼尼松联合吗替麦考酚酯治疗重症肌无力的临床疗效和安全性。方法：48例患者随机分为对照组24例和联合用药组24例，对照组给予甲基强的松龙冲击治疗后改用泼尼松维持治疗，联合用药组在对照组治疗的基础上给予口服吗替麦考酚酯分散片1g／d，分两次口服；治疗前后对患者徒手肌力和日常生活能力进行评分，并观察临床疗效和安全性。结果：与对照组相比，联合用药组MG—MMT（P〈0．05）和MG—ADL（P〈0．05）评分显著降低，临床疗效更好（P〈0．05）；两组患者均未发生严重不良反应而停药。结论：泼尼松联合吗替麦考酚酯治疗重症肌无力疗效好，治疗时闻短，临床值得推广。

Objective： To investigate the therapeutic effect and safety of Prednisone combined with Mycophenolate mofetil in patients with myasthenia gravis. Methods： 48 patients with myasthenia gravis were randomly divided into two groups： control group （n= 24） took Prednisone after Methylprednisolone pulse therapy, and combined group （n=24） took Mycophenolate mofetil lg/d based on the treatment of control group. Two group were compared with MG-MMT, MG-ADL, clinical efficacy and safety. Results： Compared with the control group, combined group MG-MMT （P〈0.05） and the MG-ADL （P〈0.05） scores were significantly lower, and better clinical efficacy （P〈0.05）; two groups of patients had no serious adverse reactions and discontinuation. Conclusion： Patients with myasthenia gravis received treatment of Prednisone combined with Mycophenolate mofetil have better clinical offective, the treatment time are shorter. It is worthy of promotion.